Illumina did $4.3B of revenue in 2025, roughly one-quarter of its $17.9B market cap, a relatively compact business.

The odd bit: the top line barely budged, down 0.7% year over year, while profitability snapped back. Operating margin in 2025 landed at 18.6% and net margin at 19.6%, reversing the deep losses seen in earlier years.

That combination changes how you read the numbers. Flat revenue keeps growth questions alive, but the margin recovery restores cash generation: operating cash flow covered net income by 1.27x in the latest year, a datapoint that matters if the company wants to fund deals or buybacks out of operations.

embed: mini_trend

The filing offers the blunt receipts. Revenue finished the year down 0.7%, yet operating margin improved by a full sweep compared with the recent loss-making period, management points to a substantial margin shift in the report.

The 10-K also drops a concrete item in a footnote: an acquisition in late January. > "SUBSEQUENT EVENTS On January 30, 2026, we acquired SomaLogic and other specified assets from Standard BioTools for a $ 350 million upfront cash payment, subject to customary adjustments." Illumina / 10-K 2026-02-12

That’s a $350 million upfront payment the company made after year‑end. The filing states the purchase but does not quantify how much revenue the acquired assets will add or how soon they will affect margins.

Put another way: Illumina’s operating margin changed by 37.6 percentage points in the latest annual period, a swing large enough to reshape free cash flow and earnings math even while sales sit essentially flat. The company is generating profit again; the open question is whether profit is back because the underlying business recovered, or because costs and prior write-downs stopped weighing on the income statement.

Those two threads, stable, slightly shrinking revenue and a sharp return to profit, are what the 10-K hands investors. There is also a newly closed, $350 million acquisition that could nudge product mix or recurring revenue, but the filing leaves the timing and scale of that effect unspecified.

Can Illumina sustain 18.6% operating margins alongside a near-flat revenue base, and how much revenue or integration cost does management expect from the SomaLogic assets?

Review it.